"Top lawyer" Neil Jenkins continues to win effusive praise from market players, reflecting his "excellent practice" focusing on cross-border patent litigation.
Neil has particular interest and expertise in the management and conduct of cross-border patent litigation and has an established reputation in the pharma and medical device fields.
Neil is a partner in Bird & Bird’s intellectual property group based in London. He joined the firm in 1986 and became a partner in 1996.
His practice is focused on patent, trademark, copyright, design and trade secret litigation. It also encompasses such associated matters as regulatory data exclusivity, supplementary protection certificates, labelling and advertising as well as domain name disputes, brand management and anti-counterfeiting.
His cases before the English courts and in the CFI include PLG v Ardon (plastic grids), ICI v Montedison (polymer composite), HCC v BP (acetic acid purification), UCC v BP (fluid bed production of polyethylene), Stephenson v Du Pont (entitlement), Hesco v Maccaferri (gabions), Chef Revival v OHIM (Chef mark), Agilent v Waters (HPLC pumps), Teva v Merck (alendronate), Teva v Merck (simvastatin), Lundbeck v Niche (citalopram), Abbott v APS (clarithromycin), Celltech v OHIM (Celltech mark), Actavis v Merck (finasteride), Actavis v Novartis (fluvastatin), Specialty Brands v OHIM (dog device), Teva v Merck (timolol/dorzolamide combination), Generics v Yeda/Teva (glatiramer acetate), Novartis v Teva (rivastigmine) and Synthon v Teva (glatiramer acetate).
Neil speaks regularly at IP conferences and contributes to the leading IP journals on many aspects of IP law and litigation. He is also the editor of International Intellectual Property Litigation (published by Butterworths).